

## RESEARCH ARTICLE

# Reduction of Cystatin B results in increased cathepsin B activity in disomic but not Trisomy 21 human cellular and mouse models

Yixing Wu<sup>1,2\*</sup>, Karen Cleverley<sup>3</sup>, Frances K. Wiseman<sup>1,2\*</sup>

**1** UK Dementia Research Institute at University College London, London, United Kingdom, **2** UCL Queen Square Institute of Neurology, Queen Square, London, United Kingdom, **3** Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, Queen Square, London, United Kingdom

\* [yixing.wu@ucl.ac.uk](mailto:yixing.wu@ucl.ac.uk) (YW); [f.wiseman@ucl.ac.uk](mailto:f.wiseman@ucl.ac.uk) (FKW)



## OPEN ACCESS

**Citation:** Wu Y, Cleverley K, Wiseman FK (2025) Reduction of Cystatin B results in increased cathepsin B activity in disomic but not Trisomy 21 human cellular and mouse models. PLoS ONE 20(1): e0316822. <https://doi.org/10.1371/journal.pone.0316822>

**Editor:** Stephan N. Witt, Louisiana State University Health Sciences Center, UNITED STATES OF AMERICA

**Received:** April 16, 2024

**Accepted:** December 16, 2024

**Published:** January 22, 2025

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0316822>

**Copyright:** © 2025 Wu et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** The manuscript has been posted as a preprint on bioRxiv bioRxiv preprint doi: <https://doi.org/10.1101/2024.04.10>.

## Abstract

Down syndrome, resulting from trisomy of human chromosome 21, is a common form of chromosomal disorder that results in intellectual disability and altered risk of several medical conditions. Individuals with Down syndrome have a greatly increased risk of Alzheimer's disease (DSAD), due to the presence of the *APP* gene on chromosome 21 that encodes the amyloid- $\beta$  precursor protein (APP). APP can be processed to generate amyloid- $\beta$ , which accumulates in plaques in the brains of people who have Alzheimer's disease and is the upstream trigger of disease. Cathepsin B has potential roles in both APP processing and amyloid- $\beta$  degradation and has been suggested to contribute to amyloid- $\beta$  accumulation. An endogenous inhibitor of Cathepsin B, Cystatin B (*CSTB*), is encoded on chromosome 21. The abundance of this protein is increased in the brains of individuals with DSAD, which may be associated with a decrease in Cathepsin B activity compared to individuals who have Alzheimer's disease in the general population. Whether targeting *CSTB* can modulate Cathepsin B activity in the context of trisomy of chromosome 21 is unclear. Here we test if reducing *CSTB* can alter Cathepsin B activity in a mouse and a cellular model of trisomy of chromosome 21. We find that reducing *CSTB* abundance increases Cathepsin B activity in disomic controls but not in the presence of trisomy of chromosome 21. These findings offer new insights into the role of *CSTB* in regulating Cathepsin B activity.

## Introduction

Individuals with Down syndrome (DS) caused by trisomy of human chromosome 21 (Hsa21) experience cognitive impairment, craniofacial abnormalities and alterations in the function of their immune system and have a significantly increased risk of developing early onset Alzheimer's disease [1]. Alzheimer's disease (AD)-associated amyloid- $\beta$  plaques develop in people with DS by age 40 [2]. This triggers a cascade of cellular and molecular changes in the brain that result in a greater increased risk of developing mid-life dementia [3]. By the age of 60, around two-thirds of the individuals with DS will have a clinical dementia diagnosis caused by AD (DSAD) [4]. Duplication of the Hsa21-located *APP* gene that encodes amyloid precursor

588836 All uncropped western blots are available at FigShare Wu et al 2024\_raw\_images.pdf. [https://figshare.com/articles/figure/Wu\\_et\\_al\\_2024\\_raw\\_images\\_pdf/25567920](https://figshare.com/articles/figure/Wu_et_al_2024_raw_images_pdf/25567920).

**Funding:** Funding Statement F.K.W., is supported by the UK Dementia Research Institute (UKDRI-1014) through UK DRI Ltd, principally funded by the UK Medical Research Council. Y. W, is supported by an Alzheimer's Research UK Senior Research Fellowship (ARUK-SRF2018A-001 and ARUK-SRFEXT2022-001) awarded to F.K.W.

**Competing interests:** NO authors have competing interests.

protein (APP) causes an overproduction of amyloid- $\beta$ , triggering its accumulation in the brain [5]. In addition, an extra copy of Hsa21 genes other than APP, also modulates the generation and accumulation of amyloid- $\beta$  [6–11].

Cysteine protease, cathepsin B (CatB) [12], has important roles in protein degradation and cellular homeostasis [13, 14]. Increased abundance and activity of the enzyme is associated with AD in the general population [15–17], particularly with the accumulation of amyloid- $\beta$  within the brain [18], and variation in the *CTSB* (CatB gene) is associated with the risk of late-onset AD [19]. CatB has been proposed to have a role in APP processing in the brain, including both the generation and catabolism of amyloid- $\beta$  [17, 20, 21], but which mechanism predominates is unclear. Notably, decreased CatB activity is associated with dysfunction of lysosomes and accumulation of APP C-terminal fragments (CTFs) and amyloid- $\beta$  [22, 23], phenotypes also associated with the early stages of DSAD [24]. We have previously found that CatB activity is reduced in the brain of individuals with DSAD compared with matched cases of EOAD from the general population [15]. Thus, normalising CatB activity may be a therapeutic strategy for the treatment of the early stages of DSAD.

The endogenous inhibitor of CatB, Cystatin B (CSTB), is encoded on Hsa21. Individuals who lack two functional copies of *CSTB*, develop a genetic form of epilepsy called Unverricht-Lundborg disease, that is progressive and associated with neurodegeneration. Cells isolated from individuals with Unverricht-Lundborg disease and animal models that lack functional *Cstb* exhibit reduced CatB activity [23, 25]. Trisomy of Hsa21 increases the abundance of CSTB in the brains of people with DSAD and in fibroblasts from individuals with DS [15]. Elevated levels of CSTB may contribute to the altered activity of CatB that is observed in DSAD, leading to dysregulated proteolysis and downstream effects on neuropathological features of AD. Although, an additional copy of *Cstb* is not sufficient to reduce CatB activity in the brain of DS mouse models, or in trisomy 21 fibroblasts under basal conditions [15, 26]. Whether lowering CSTB abundance in the context of trisomy of Hsa21 is sufficient to elevate CatB activity is unknown. Here we used human cellular and mouse models to investigate this.

## Materials and methods

### Mouse welfare and husbandry

Heterozygous *Cstb* knockout mice (*Cstb*<sup>tm1b(EUCOMM)Wtsi</sup> named here *Cstb*<sup>+/-</sup>) (MGI:5790639) were kindly supplied by the MRC Mary Lyon Centre, and maintained by mating male *Cstb*<sup>+/-</sup> to female C57BL/6J for one generation prior to crossing the progeny of this cross to Tc1 mice. Tc1 (Tc(HSA21)1TybEmcf/J) mice were taken from a colony maintained by mating Tc1 females (MGI: 3814712) to F1 (129S8 × C57BL/6) males. To generate the cohort studied here *Cstb*<sup>+/-</sup> males were mated with Tc1 females to produce four genotypes referred to as: wild-type (WT), *Cstb*<sup>+/-</sup>, Tc1, and Tc1;*Cstb*<sup>+/-</sup>. We ensured that no *Cstb*<sup>-/-</sup> animals were generated during our study because of adverse welfare outcomes associated with this genotype. In this study, all mice were housed in controlled conditions as per the Medical Research Council (MRC) and University College London (UCL)'s guidance. All experiments were conducted with approval from the Local Ethical Review panel and under License from the UK Home Office. Mice were semi-randomised by Mendelian inheritance of the genetically altered alleles into cages housing one sex, with at least two mice per cage. All mice were provided with bedding and wood chips, and continuous access to water. RM1 and RM3 chow were provided to breeding and stock mice, respectively by Special Diet Services, UK. Individually ventilated cages were in a specific-pathogen-free facility. Euthanasia of mice was carried out by exposing them to gradually increasing levels of CO<sub>2</sub> gas, and confirmation of death by dislocation of the neck, in compliance with the Animals (Scientific Procedures) Act issued in the United Kingdom in 1986.

## Genotyping

DNA was extracted from ear biopsies by the Hot Shot method [27]. Mice were genotyped using polymerase chain reaction (PCR) for the presence of human chromosome 21 (Tc1 specific primers f: 5'-GGTTTGAGGGGAACACAAAGCTTAACTCCCA-3' r: 5'-ACAGAGCTACAGCCTCTGACACTATGAACT-3', control primers f: 5'-TTACGTCCATCGTGGACAGCAT-3' r: 5'-TGGGCTGGGTGTTAGTCTTAT-3') as described previously [28]. Mice were genotyped by PCR for the presence of the *Cstb*<sup>-</sup> (KO) and *Cstb*<sup>+</sup> (WT) alleles with (*Cstb*-5arm-WT f: 5'-GTAGGGGAGGTTTCAGGGTA-3', *Cstb*-Crit-WT r: 5'-GGCTGGCATGGAAC TAAGCA-3' and 5-KO r: 5'-GAACTTCGGAATAGGAACTTCG-3').

## Cell culture

Cultured human fibroblasts derived from four individuals with Down syndrome (DS) (AG05397, AG07438, AG04823, and AG06922) and four euploid controls (GM05399, GM05565, GM05658 and GM05758) (Coriell Biorepository) were cultivated in Dulbecco's Modified Eagle Medium (DMEM). The DMEM was supplemented with 10% fetal bovine serum (FBS) and 100 units/ml of penicillin-streptomycin (Thermo Fisher Scientific). The cells were grown at 37°C in an environment with 5% CO<sub>2</sub>.

When the cells reached about 70% confluency, they were harvested through trypsinization using Gibco™ Trypsin-EDTA (0.25%), phenol red at 37°C. Subsequently, the cells were collected, pelleted, and washed three times using phosphate-buffered saline (PBS) before being homogenised.

## Dharmafect-mediated gene knockdown

Dharmacon™ siRNA (Horizon) knockdown of *CSTB* in human fibroblasts was conducted as per the manufacturer's instructions with minor changes. In brief, a 5 μM siRNA solution (ON-TARGETplus Non-targeting Pool, Catalogue number: D-001810-10-05, ON-TARGETplus GAPDH Control Pool (Human), Catalogue number: D-001830-10-05, or ON-TARGETplus Human *CSTB* (1476) siRNA -SMARTpool, Catalogue number: L-017240-00-0005) was prepared using RNase-free water by diluting from the stock solution. Two separate tubes were used to dilute the siRNA (Tube 1) and the DharmaFECT (Horizon) transfection reagent (Tube 2) using serum-free medium. In Tube 1, a 200 μl diluted siRNA solution (for each well of a 6-well plate) was prepared in serum-free DMEM medium by combining 10 μl of 5 μM siRNA with 190 μl of serum-free medium. In Tube 2, a 200 μl diluted DharmaFECT transfection reagent solution was prepared in serum-free medium. The DharmaFECT reagent amounts used were 1 μl, 2.5 μl and 5 μl per well of a 6-well plate. The contents in Tube 1 and 2 were then mixed and incubated for 5 minutes at room temperature. The contents from Tube 1 were then added to Tube 2, and gently mixed by pipetting prior to a further incubation for 20 minutes at room temperature. After incubation, the transfection medium was added to each well of the 6 well plate (final concentration of siRNA: 25nM). The cells were incubated at 37°C with 5% CO<sub>2</sub> for 48 hours prior to analysis.

## Western blotting

To assess protein levels, the mouse cortex was homogenised using CB lysis buffer from the Cathepsin B Activity Assay Kit (Abcam, ab65300), with the addition of cComplete™ Protease Inhibitor (Roche). Protein concentration was determined using a Bradford assay (Bio-Rad).

Mouse cortical homogenates were denatured using NuPAGE LDS Sample Buffer and NuPAGE™ Sample Reducing Agent (Thermo Fisher Scientific) at 95°C for 5 minutes. They

were subsequently separated through SDS-polyacrylamide gel electrophoresis on a NuPAGE Novex 4–12% Bis-Tris gel (Thermo Fisher Scientific) at 150V for 50 minutes. The proteins were then transferred from the gel to a nitrocellulose membrane using the Trans-Blot Turbo™ Transfer System (Bio-Rad) at 25V, 2.5A for 7 minutes. Following transfer, the membranes were blocked using Intercept Blocking Buffer (LI-COR Bioscience) for 1 hour at room temperature.

For antibody probing, the membranes were incubated with primary antibodies overnight at 4°C. The primary antibodies used were rabbit polyclonal anti-human Cystatin B (Abcam, ab236646, 1:2,000), rat monoclonal anti-mouse Cystatin B (Novus Biologicals, USA, #227818 (MAB1409), 1:2,000), rabbit polyclonal anti-cathepsin B (Abcam, ab92955, 1:1,000), rabbit monoclonal anti-GAPDH (Sigma, G9545, 1:5,000) and mouse monoclonal anti- $\beta$ -actin antibody (Sigma-Aldrich, #A5441, 1:10,000). This was followed by incubation with secondary antibodies for 1 hour at room temperature. The secondary antibodies were IRDye 800CW Goat anti-Rabbit IgG (H + L) (1:10,000), Goat anti-Rat IRDye® 800CW IgG (H + L) and IRDye 680RD Goat anti-Mouse IgG (H + L) (1:10,000) (LI-COR Biosciences). Membranes were visualised using an Odyssey CLx Infrared Imaging System. The density of protein bands was quantified using ImageJ software.

For normalisation, the density of the CSTB or CatB protein band was divided by the density of the corresponding  $\beta$ -actin band run in the same lane. All uncropped western blots are available at FigShare Wu et al 2024\_raw\_images.pdf and as [S1 Fig](#).

### Cathepsin B enzyme activity assay

The activity of CatB was examined in the cortex of 3-month-old mice or human fibroblasts using a Cathepsin B Activity Assay Kit (Abcam, #ab65300). The tissue or fibroblasts were homogenised in CB lysis buffer and then incubated on ice for 30 minutes before being centrifuged at 15,000 x g for 5 minutes at 4°C. The resulting supernatant was transferred to a clean tube and protein concentration was determined using a Bradford assay (Bio-Rad). 200  $\mu$ g tissue homogenate or 10  $\mu$ g cell lysate was diluted in 50  $\mu$ l CB lysis buffer and was used for the reaction with CatB Substrate (RR-amino-4-trifluoromethyl coumarin (AFC)).

To measure nonspecific cleavage, samples were treated with 50  $\mu$ M inhibitors ALLM (Abcam, ab141446) or Z-Phe-Phe-FMK (Abcam, ab141386). The reaction mixture was then incubated at 37°C in a microplate reader (Tecan), and the resulting fluorescent signal (excitation/emission = 400/505nm) was recorded every 90 seconds for 30 cycles by the microplate reader. The linear part of the reaction was determined, and the relative CatB activity in the sample was calculated by determining the average fluorescent output for each sample and subtracting the matched output from the inhibited reaction. Means of technical replicates were calculated for each individual sample, with biological replicate being used as the experimental unit. For CatB assays, 1 and 6 technical replicates were used for mouse cortex samples and human fibroblasts, respectively.

### Statistical analysis

All mouse experiments and data analyses were carried out blind to both genotype and sex. A unique 6-digit identifier was assigned to all mice and their homogenate tissue samples. Individual mouse or independent cell line were used as the experimental unit for all analysis.


The data are presented as group mean  $\pm$  SEM, with individual datapoints for biological replicates. Data were analysed by ANOVA, using the mean of technical replicates, as indicated in the figure legends. For fibroblast studies variables of trisomy 21 status and treatment (control, *CSTB* knockdown or *GAPDH* knockdown) were used. For mouse studies variables of sex,

trisomy 21 status and *Cstb*<sup>+/-</sup> status were used. Pairwise comparisons for variables with more than two variants, with correction for multiple comparison as indicated in the figure legends, was undertaken when significant main effects or interactions were observed. Analyses were performed using GraphPad Prism 9 software (GraphPad Software) and SPSS version 26. Statistical significance was determined with a threshold of  $p < 0.05$ .

## Results

### CSTB knockdown increases CatB activity in disomic but not trisomy 21 human fibroblasts

To determine if targeting the endogenous inhibitor of CatB, CSTB, might be a viable strategy to increase cathepsin B activity in the context of trisomy of Hsa21, we used a siRNA approach to reduce CSTB abundance in human fibroblasts isolated from individuals with DS and matched euploid controls. We first optimized transfection conditions using a non-targeting negative control, GAPDH or CSTB siRNAs. A 1:400 dilution of transfection reagent was required to reduce GAPDH and CSTB abundance robustly in both disomic and trisomy 21 cells (Fig 1 and S2 Fig). To determine the effect of CSTB knockdown on CatB activity, a



**Fig 1. CSTB knockdown and CatB activity in disomic and trisomy 21 human fibroblasts.** Western blot of CSTB (A) and GAPDH (B) normalised to  $\beta$ -actin in disomic and trisomy 21 human fibroblasts. (C) Trisomy 21 increased CSTB abundance in control and *GAPDH* KD groups (ANOVA main effect of Trisomy 21  $F(1,18) = 41.92$ ,  $p < 0.0001$ , pairwise with Tukey correction control  $p < 0.0001$ , *GAPDH* KD  $p = 0.0002$ ). DharmaFECT-mediated knockdown reduced CSTB abundance compared with the control and the *GAPDH* KD groups (ANOVA main effect treatment  $F(2,18) = 73.50$ ,  $p < 0.0001$ , pairwise with Tukey correction control versus CSTB knockdown  $p < 0.0001$  (disomic and trisomy 21), *GAPDH* versus CSTB knockdown  $p < 0.0001$  (disomic and trisomy 21)). (D) DharmaFECT-mediated knockdown significantly reduced GAPDH compared with the control group and the *CSTB* KD group (ANOVA main effect treatment  $F(2,18) = 19.04$ ,  $p < 0.0001$ , pairwise with Tukey correction control versus *GAPDH* knockdown  $p = 0.0133$  (disomic),  $p = 0.0002$  (trisomy 21), *GAPDH* versus *CSTB* knockdown  $p = 0.0051$  (disomic)  $p = 0.0259$  (trisomy 21)). (E) *CSTB* knockdown significantly increases CatB activity compared with the control group and the *GAPDH* KD group in disomic, but not trisomy 21, fibroblasts as measured by the rate of cleavage of Ac-RR-AFC, corrected for nonspecific activity in samples inhibited by ALLM. (ANOVA interaction of treatment and trisomy  $F(2,12) = 4.621$ ,  $p = 0.0325$ , pairwise with Tukey control versus *CSTB* knock-down  $p = 0.0418$  (disomic)). Data are shown as  $\pm$ SEM of group means for 4 disomic and 4 trisomy 21 lines (6 technical replicates for *CSTB* KD western blots, 4 technical replicates for *GAPDH* KD western blots and 2 technical replicates for CatB activity assay). \* $p < 0.05$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

<https://doi.org/10.1371/journal.pone.0316822.g001>

substrate (Ac-RR-AFC) cleavage assay was used and the mean rate of cleavage relative to the disomic control was calculated for all conditions. The siRNA-mediated reduction in CSTB abundance led to an increase in CatB enzyme activity in disomic, but not in trisomy 21 human fibroblasts (Fig 1E), despite the abundance of CSTB after knockdown not differing between disomic and trisomy 21 cells. Thus, targeting *CSTB* in trisomy 21 fibroblasts does not have a direct impact on CatB activity, in contrast to the effect of reducing this endogenous inhibitor on enzyme activity in disomic cells.

### CSTB knockdown does not affect the maturation of cathepsin B


Cathepsin B undergoes a maturation process by cleaving its proenzyme form to generate the mature active enzyme [29]. To test whether the reduction of CatB activity in disomic cells, mediated by *CSTB* knock-down, changed enzyme processing, the abundance of pro and mature CatB protein was measured by western blot (Fig 2A). Knocking down *CSTB* does not alter the protein level of pro-CatB, mature CatB or the mature CatB/pro-CatB ratio, compared with both untransfected controls and GAPDH knock-down in either disomic or trisomy 21 cells (Fig 2B–2D). These results suggest that the maturation of cathepsin B was unaffected by *CSTB* knockdown and thus changes to CatB activity in disomic fibroblasts occur via another process, likely mediated by a direct interaction between the endogenous inhibitor and enzyme.

### *Cstb* gene copy reduction leads to elevated CatB activity in the mouse brain but not in the presence of trisomy 21

To further understand the interaction of *CSTB* abundance, cathepsin B activity and trisomy of chromosome 21, we studied the effect of *Cstb* gene dose on CatB activity in a mouse model of DS. To do this we crossed the Tc1 mouse model of DS with *Cstb*<sup>+/-</sup> mice. The Tc1 mouse carries a copy of human chromosome 21, including an additional copy of human *CSTB*, alongside a normal complement of mouse chromosomes [28]. Thus, it contains 3 copies of the *CSTB/Cstb* gene and can be used to understand the effect of this on trisomy 21 biology. Importantly, this mouse model does not carry an additional functional copy of *APP* [30], and does not have raised abundance of *APP* in the brain [10], therefore it can be used to understand the effect of trisomy 21 independently of the effect of an additional copy of *APP*. The cross of Tc1 and *Cstb*<sup>+/-</sup> mice generated progeny with four genotypes: wildtype (WT) (2-copies of *Cstb*), Tc1 (3-copies of *CSTB/Cstb*), *Cstb*<sup>+/-</sup> (1-copy of *Cstb*) and Tc1;*Cstb*<sup>+/-</sup> ((2-copies of *CSTB/Cstb*).

We quantified the abundance of both mouse (Fig 3A) and human (Fig 3B) *CSTB* in total cortical proteins from these mice at 3-months of age. Human euploid and trisomic fibroblast homogenates were used to control for the specificity of the anti-mouse *CSTB* antibody (Fig 3A). Similarly, negligible signal was detected with the anti-human *CSTB* antibody in cortical samples from mice that did not express the human version of the protein (WT and *Cstb*<sup>+/-</sup>) (Fig 3B). We found a significant decrease in mouse *CSTB* in *Cstb*<sup>+/-</sup> and Tc1;*Cstb*<sup>+/-</sup> cortices compared to WT and Tc1 controls (Fig 3A and 3D). Human *CSTB* levels were significantly higher in Tc1 and Tc1;*Cstb*<sup>+/-</sup> cortices than WT and *Cstb*<sup>+/-</sup> controls, with no difference observed between the Tc1 and Tc1;*Cstb*<sup>+/-</sup> samples (Fig 3E). Thus, reduction in *Cstb* gene copy number from two to one, or three to two, reduces the overall abundance of protein in the cortex of both the disomic and trisomy 21 mice respectively.

To investigate whether the reduction of *Cstb* has an effect on CatB maturation, the abundance of pro-CatB and mature CatB was quantified by western blot. No difference in pro-CatB or mature CatB protein abundance, or the mature cathepsin B/pro-CatB ratio was observed (Fig 3F–3H). Therefore, consistent with our findings in human fibroblasts, *Cstb* gene copy




**Fig 2. Protein levels of pro and mature CatB in disomic and trisomy 21 human fibroblasts.** (A) Representative western blots of the proteins of pro-CatB and mature CatB, normalised to  $\beta$ -actin in disomic and trisomy 21 human fibroblasts. (B-D) DharmaFECT-mediated knockdown of *CSTB* does not alter the protein level of (B) pro-CatB, (C) mature CatB or (D) mature CatB/pro-CatB ratio compared with the control group and the *GAPDH* KD group. Data are shown  $\pm$ SEM of group means for 4 disomic and 4 trisomy 21 lines (5 technical replicates for western blots). Data were analysed by two-way ANOVA followed by Tukey's post-hoc tests.

<https://doi.org/10.1371/journal.pone.0316822.g002>

reduction does not alter CatB maturation in the cortex of either disomic or trisomy 21 mice at 3 months of age.

To determine how *Cstb* gene dose affected CatB activity, we undertook a biochemical cleavage assay on samples of mouse cortex at 3-months of age. The mean rate of CatB activity, corrected for non-specific activity using either ALLM or FMK inhibitors, was calculated for each genotype relative to the WT mean rate. CatB activity in *Cstb*<sup>+/-</sup> mice was significantly increased compared with WT, Tc1 and Tc1;*Cstb*<sup>+/-</sup> controls (Fig 3I and 3J), demonstrating that a reduction in the copy number of *Cstb* from two to one copies results in increased CatB activity within the disomic mouse brain. However, there was no difference in CatB activity between



**Fig 3. CSTB and CatB abundance, and CatB activity in the brain of WT, *Cstb*<sup>+/-</sup>, *Tc1* and *Tc1*;*Cstb*<sup>+/-</sup> cortex.** Representative western blots of (A) mouse CSTB (mCSTB), (B) human CSTB (hCSTB), (C) pro-CatB and mature CatB in cortex homogenate of WT, *Cstb*<sup>+/-</sup>, *Tc1* and *Tc1*;*Cstb*<sup>+/-</sup> mice. The relative intensity of mCSTB, hCSTB, pro-CatB or mature CatB was quantified by normalising it with  $\beta$ -actin. (D) The abundance of mCSTB is lower in *Cstb*<sup>+/-</sup> and *Tc1*;*Cstb*<sup>+/-</sup> compared with WT and *Tc1* controls (ANOVA *Cstb*<sup>+/-</sup> genotype main-effect F(1,31) = 5.857, p = 0.022, pairwise comparison with Hochberg correction WT compared *Cstb*<sup>+/-</sup> p = 0.043, *Tc1* compared *Tc1*;*Cstb*<sup>+/-</sup> p = 0.006, *Tc1* compared *Cstb*<sup>+/-</sup> p < 0.001). (E) The abundance of hCSTB was higher in *Tc1* and *Tc1*;*Cstb*<sup>+/-</sup> than WT and *Cstb*<sup>+/-</sup> controls (ANOVA *Tc1*



genotype main-effect  $F(1,31) = 383.733$ ,  $p < 0.001$ , pairwise comparison with Hochberg correction WT/*Cstb*<sup>+/-</sup> compared Tc1  $p < 0.001$ , *Cstb*<sup>+/-</sup> compared Tc1;*Cstb*<sup>+/-</sup>  $p < 0.001$ ). No difference in the abundance of (F) proCatB, (G) mature CatB or (H) the mature CatB/pro-CatB ratio was detected in the WT, *Cstb*<sup>+/-</sup>, Tc1 and Tc1;*Cstb*<sup>+/-</sup> cortex. (I) CatB activity as measured by biochemical assay (rate of cleavage of Ac-RR-AFC corrected for (I) ALLM or (J) FMK. (I) CatB activity differed between genotypes (ANOVA Tc1 genotype main-effect  $F(1,30) = 16.583$ ,  $p < 0.001$ , pairwise comparison with Hochberg correction *Cstb*<sup>+/-</sup> compared Tc1  $p = 0.001$ , *Cstb*<sup>+/-</sup> compared Tc1;*Cstb*<sup>+/-</sup>  $p = 0.001$ ). (J) CatB activity differed between genotypes (ANOVA Tc1 genotype main-effect  $F(1,30) = 16.106$ ,  $p < 0.001$ , pairwise comparison with Hochberg correction WT compared *Cstb*<sup>+/-</sup>  $p = 0.048$ , *Cstb*<sup>+/-</sup> compared Tc1  $p = 0.001$ , *Cstb*<sup>+/-</sup> compared Tc1;*Cstb*<sup>+/-</sup>  $p = 0.001$ ). (A-H) 10 WT (5 female 5 male), 10 *Cstb*<sup>+/-</sup> (3 female, 7 male), 9 Tc1 (3 female, 6 male) and 10 Tc1;*Cstb*<sup>+/-</sup> (4 female, 6 male) mice. (I, J) 10 WT (5 female, 5 male), 10 *Cstb*<sup>+/-</sup> (3 female, 7 male), 9 Tc1 (3 female, 6 male) and 9 Tc1;*Cstb*<sup>+/-</sup> (4 female, 5 male) mice. 2–3 technical replicates for western blots and 2 technical replicates for CatB activity assay). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , error bars SEM.

<https://doi.org/10.1371/journal.pone.0316822.g003>

the Tc1 and Tc1;*Cstb*<sup>+/-</sup> groups (Fig 3I and 3J). Thus, reducing the *Cstb* gene copy number from three to two copies in the presence of trisomy 21 in the young adult cortex does not modify CatB activity.

## Discussion

The interaction between CSTB and CatB plays an important role in balancing proteolytic activity within cells [25]. In this study, we investigated whether altering this balance by either reducing protein levels of CSTB using siRNA-mediated knockdown or reducing the number of copies of the *Cstb* gene, can lead to an increase in CatB activity, or a change in CatB maturation, in the context of trisomy of Hsa21. Our results showed that in disomic human fibroblasts, knocking down *CSTB* increases CatB activity. Similarly, reducing *Cstb* from two to one copy in mice also leads to an increase in CatB activity in the young adult cortex, consistent with a previous report [23]. In contrast, in the presence of trisomy 21, knocking down *CSTB* in human fibroblasts or lowering *Cstb* gene dose in a mouse model of DS, from three to two copies, does not alter CatB activity.

Previously, we have shown that an additional copy of *Cstb/CSTB* is not sufficient to alter CatB activity in a range of DS preclinical models [15, 26]. Here, we show that in the context of trisomy of Hsa21, less *CSTB* is also not sufficient to modify enzyme activity, in contrast to the effect of the copy number of this gene in disomic cells and brain. This may be the result of other regulators of CatB activity being differentially regulated by trisomy 21. For example, cystatin C (*CST3*) also modulates CatB activity [21, 31, 32], and has been reported to be upregulated by trisomy 21 [33]. However, in the Ts2Cje mouse model of DS overexpressing *CST3* improved endosomal morphology and alleviated behavioural defects but does not alter CatB activity [34], indicating that increased abundance of this cystatin may also be insufficient to change CatB activity in the context of DS.

We have previously shown that in human temporal cortex CatB activity is lower in cases of DSAD compared with cases of early-onset AD from the general population [15]. The difference between these data and the findings in our preclinical models indicates that the effect of trisomy 21 on CatB activity could depend on the development of AD neuropathology, which includes accumulation of misfolded amyloid- $\beta$  and tau. Further research in DSAD model systems is warranted to understand this complex biology. However, here we highlight that in trisomy 21 preclinical systems, in the absence of features of AD neuropathology, targeting *CSTB* is not sufficient to increase CatB activity. These data indicate that trisomy 21 alters the effect of lowering *CSTB* abundance independently of AD neuropathology.

In addition to cystatins, CatB activity is also regulated by the processing of the enzyme. Here we show, consistent with our previous work, that CatB processing as measured by the pro/mature ratio is not affected by trisomy 21 [15]. Thus, another mechanism likely results in the insensitivity of CatB activity to *CSTB* abundance in the context of trisomy 21. Trisomy 21

results in perturbations to endo-lysosomal biology, in part because of an effect of APP-CTF on v-ATPase acidification [35]. Notably, the Tc1 mouse model does not have an additional functional copy of *APP*, thus raised APP-CTF is unlikely to be the cause of the insensitivity to *Cstb* gene dose that we observed.

In our DS mouse model we reduced the *CSTB/Cstb* gene from three to two copies, rather than three copies to one copy. This is a limitation of our study, and reduction to only one copy of the gene, by deletion of both copies of mouse *Cstb*, may be required to modify CatB activity in the brain. We note that the deletion of both copies of *Cstb* in the mouse, recapitulates many features of Unverricht-Lundborg disease, including seizures, progressive ataxia and neurodegeneration [36, 37]. Thus, in our preclinical systems we aimed to reduce but not completely eliminate CSTB protein, to avoid inducing features of Unverricht-Lundborg disease.

In summary, results from our study indicate the complexity of the relationship between CSTB, CatB, and trisomy 21. While reducing the abundance of CSTB increased CatB activity in disomic human fibroblasts and mouse brain, this effect is not replicated in the presence of trisomy 21, suggesting that *CSTB* gene dose does not contribute to the regulation of CatB activity in people who have DS. Thus, targeting CSTB is unlikely to be a useful strategy to normalize CatB activity in the context of DS.

## Supporting information

### S1 Fig. Uncropped western blot files for all figures in this manuscript.

(PDF)

### S2 Fig. *CSTB* and *GAPDH* knockdown in disomic and trisomy 21 human fibroblasts using different concentrations of DharmaFECT transfection reagent.

(A-B) Western blot of *CSTB* and *GAPDH* normalised to  $\beta$ -actin in disomic and trisomy 21 human fibroblasts in (A) 1:2,000 dilution of DharmaFECT reagent or (B) 1:800 dilution DharmaFECT reagent. (C) 1:2,000 dilution of DharmaFECT-mediated *CSTB* knockdown reduced *CSTB* abundance compared with the control group ( $p = 0.0058$ ) in the disomic, but not in the trisomy 21 fibroblasts. (D) 1:800 dilution of DharmaFECT-mediated *CSTB* knockdown reduced *CSTB* abundance in the *CSTB* KD group compared with the *GAPDH* KD group ( $p = 0.0139$ ), but not compared to the control group in the trisomic 21 human fibroblasts or the disomic group. (E) 1:2000 dilution of DharmaFECT-mediated *GAPDH* knockdown does not affect *GAPDH* abundance in either disomic or trisomy 21 fibroblasts. (F) 1:800 dilution of DharmaFECT-mediated *GAPDH* knockdown reduced *GAPDH* abundance in disomic fibroblasts compared to control ( $p = 0.002$ ) and *CSTB* ( $p = 0.0028$ ) groups. In the trisomy 21 fibroblasts, *GAPDH* knockdown reduced *GAPDH* abundance compared with the control ( $p = 0.0025$ ), but not the *CSTB* knockdown group. Data are shown as  $\pm$ SEM of group means for 4 disomic and 4 trisomy 21 lines (1 technical replicate for western blots). Data were analysed by two-way ANOVA followed by Tukey's post-hoc tests, \* $p < 0.05$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

(TIF)

## Acknowledgments

We thank Dr. T. Cunningham (MRC Mouse Genetics Unit and Institute of Prion diseases, University College London) for help with this project. For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

## Author Contributions

**Conceptualization:** Frances K. Wiseman.

**Formal analysis:** Yixing Wu, Frances K. Wiseman.

**Funding acquisition:** Frances K. Wiseman.

**Investigation:** Yixing Wu, Frances K. Wiseman.

**Methodology:** Yixing Wu, Karen Cleverley, Frances K. Wiseman.

**Project administration:** Frances K. Wiseman.

**Resources:** Frances K. Wiseman.

**Software:** Frances K. Wiseman.

**Supervision:** Frances K. Wiseman.

**Validation:** Yixing Wu.

**Writing – original draft:** Yixing Wu, Frances K. Wiseman.

**Writing – review & editing:** Yixing Wu, Karen Cleverley, Frances K. Wiseman.

## References

1. Wiseman FK, Alford KA, Tybulewicz VL, Fisher EM. Down syndrome—recent progress and future prospects. *Hum Mol Genet.* 2009; 18(R1):R75–83. <https://doi.org/10.1093/hmg/ddp010> PMID: 19297404.
2. Head E, Lott IT. Down syndrome and beta-amyloid deposition. *Current Opinion in Neurology.* 2004; 17(2):95–100. 00019052-200404000-00003. <https://doi.org/10.1097/00019052-200404000-00003> PMID: 15021233
3. Schupf N, Sergievsky GH. Genetic and host factors for dementia in Down's syndrome. *Br J Psychiatry.* 2002; 180:405–10. <https://doi.org/10.1192/bjp.180.5.405> PMID: 11983636.
4. McCarron M, McCallion P, Reilly E, Mulryan N. A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome. *Journal of Intellectual Disability Research.* 2014; 58(1):61–70. <https://doi.org/10.1111/jir.12074> PMID: 23902161
5. Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, et al. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. *Alzheimers Dement.* 2022; 18(6):1203–34. Epub 20211110. <https://doi.org/10.1002/alz.12463> PMID: 34757693.
6. García-Cerro S, Rueda N, Vidal V, Lantigua S, Martínez-Cué C. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes. *Neurobiol Dis.* 2017; 106:76–88. Epub 20170621. <https://doi.org/10.1016/j.nbd.2017.06.010> PMID: 28647555.
7. Alić I, Goh PA, Murray A, Portelius E, Gkanatsiou E, Gough G, et al. Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. *Mol Psychiatry.* 2021; 26(10):5766–88. Epub 20200710. <https://doi.org/10.1038/s41380-020-0806-5> PMID: 32647257.
8. Mumford P, Tosh J, Anderle S, Gkanatsiou Wikberg E, Lau G, Noy S, et al. Genetic Mapping of APP and Amyloid- $\beta$  Biology Modulation by Trisomy 21. *J Neurosci.* 2022; 42(33):6453–68. Epub 20220714. <https://doi.org/10.1523/jneurosci.0521-22.2022> PMID: 35835549.
9. Tosh JL, Rhymes ER, Mumford P, Whittaker HT, Pulford LJ, Noy SJ, et al. Genetic dissection of down syndrome-associated alterations in APP/amyloid- $\beta$  biology using mouse models. *Sci Rep.* 2021; 11(1):5736. Epub 20210311. <https://doi.org/10.1038/s41598-021-85062-3> PMID: 33707583.
10. Wiseman FK, Pulford LJ, Barkus C, Liao F, Portelius E, Webb R, et al. Trisomy of human chromosome 21 enhances amyloid- $\beta$  deposition independently of an extra copy of APP. *Brain.* 2018; 141(8):2457–74. <https://doi.org/10.1093/brain/awy159> PMID: 29945247
11. Zheng Q, Song B, Li G, Cai F, Wu M, Zhao Y, et al. USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and A $\beta$  generation. *J Clin Invest.* 2022; 132(5). <https://doi.org/10.1172/jci152170> PMID: 35229730.
12. Turk V, Bode W. The cystatins: protein inhibitors of cysteine proteinases. *FEBS Lett.* 1991; 285(2):213–9. [https://doi.org/10.1016/0014-5793\(91\)80804-c](https://doi.org/10.1016/0014-5793(91)80804-c) PMID: 1855589.

13. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. *The EMBO Journal*. 2001; 20(17):4629–33. <https://doi.org/10.1093/emboj/20.17.4629> PMID: 11532926
14. Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management. *Cells*. 2020; 9(7). Epub 20200713. <https://doi.org/10.3390/cells9071679> PMID: 32668602.
15. Wu Y, Mumford P, Noy S, Cleverley K, Mrzyglod A, Luo D, et al. Cathepsin B abundance, activity and microglial localisation in Alzheimer's disease-Down syndrome and early onset Alzheimer's disease; the role of elevated cystatin B. *Acta Neuropathologica Communications*. 2023; 11(1):132. <https://doi.org/10.1186/s40478-023-01632-8> PMID: 37580797
16. Stoka V, Turk V, Turk B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. *Ageing Res Rev*. 2016; 32:22–37. Epub 20160426. <https://doi.org/10.1016/j.arr.2016.04.010> PMID: 27125852.
17. Hook G, Kindy M, Hook V. Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid- $\beta$  in hA $\beta$ PP Mouse Models Representing the Major Sporadic Alzheimer's Disease Condition. *J Alzheimers Dis*. 2023; 93(1):33–46. <https://doi.org/10.3233/jad-221005> PMID: 36970896.
18. Yuyama K, Sun H, Fujii R, Hemmi I, Ueda K, Igeta Y. Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis. *Brain*. 2024; 147(2):627–36. <https://doi.org/10.1093/brain/awad361> PMID: 38071653.
19. Bellenguez C, Küçükali F, Jansen IE, Kleiideam L, Moreno-Grau S, Amin N, et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet*. 2022; 54(4):412–36. Epub 20220404. <https://doi.org/10.1038/s41588-022-01024-z> PMID: 35379992.
20. Embury CM, Dyavarshetty B, Lu Y, Wiederin JL, Ciborowski P, Gendelman HE, Kiyota T. Cathepsin B Improves  $\beta$ -Amyloidosis and Learning and Memory in Models of Alzheimer's Disease. *J Neuroimmune Pharmacol*. 2017; 12(2):340–52. Epub 20161213. <https://doi.org/10.1007/s11481-016-9721-6> PMID: 27966067.
21. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, et al. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. *Neuron*. 2008; 60(2):247–57. <https://doi.org/10.1016/j.neuron.2008.10.001> PMID: 18957217.
22. Cermak S, Kosicek M, Mladenovic-Djordjevic A, Smiljanic K, Kanazir S, Hecimovic S. Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-Like Cholesterol Sequestration and Accumulation of the Key Alzheimer's Proteins. *PLOS ONE*. 2016; 11(11):e0167428. <https://doi.org/10.1371/journal.pone.0167428> PMID: 27902765
23. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. *Brain*. 2011; 134(Pt 1):258–77. <https://doi.org/10.1093/brain/awq341> PMID: 21186265.
24. Jiang Y, Sato Y, Im E, Berg M, Bordi M, Darji S, et al. Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP- $\beta$ CTF (C99). *J Neurosci*. 2019; 39(27):5255–68. Epub 20190501. <https://doi.org/10.1523/jneurosci.0578-19.2019> PMID: 31043483.
25. Rinne R, Saukko P, Järvinen M, Lehesjoki A-E. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy. *Annals of Medicine*. 2002; 34(5):380–5. <https://doi.org/10.1080/078538902320772124> PMID: 12452481
26. Wu Y, Whittaker HT, Noy S, Cleverley K, Brault V, Hérault Y, et al. The effects of Cstb duplication on APP/amyloid- $\beta$  pathology and cathepsin B activity in a mouse model. *PLOS ONE*. 2021; 16(7): e0242236. <https://doi.org/10.1371/journal.pone.0242236> PMID: 34292972
27. Truett GE, Heeger P, Mynatt RL, Truett AA, Walker JA, Warman ML. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). *Biotechniques*. 2000; 29(1):52, 4. <https://doi.org/10.2144/00291bm09> PMID: 10907076.
28. O'Doherty A, Ruf S, Mulligan C, Hildreth V, Errington ML, Cooke S, et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. *Science*. 2005; 309(5743):2033–7. <https://doi.org/10.1126/science.1114535> PMID: 16179473.
29. Rozman J, Stojan J, Kuhelj R, Turk V, Turk B. Autocatalytic processing of recombinant human pro-cathepsin B is a bimolecular process. *FEBS Lett*. 1999; 459(3):358–62. [https://doi.org/10.1016/s0014-5793\(99\)01302-2](https://doi.org/10.1016/s0014-5793(99)01302-2) PMID: 10526165.
30. Gribble SM, Wiseman FK, Clayton S, Prigmore E, Langley E, Yang F, et al. Massively parallel sequencing reveals the complex structure of an irradiated human chromosome on a mouse background in the Tc1 model of Down syndrome. *PLoS One*. 2013; 8(4):e60482. <https://doi.org/10.1371/journal.pone.0060482> PMID: 23596509.
31. Cimerman N, Prebanda MT, Turk B, Popovič T, Dolenc I, Turk V. Interaction of cystatin C variants with papain and human cathepsins B, H and L. *Journal of enzyme inhibition*. 1999; 14(2):167–74. <https://doi.org/10.3109/14756369909036552> PMID: 10445041

32. Kaur G, Mohan P, Pawlik M, DeRosa S, Fajiculay J, Che S, et al. Cystatin C Rescues Degenerating Neurons in a Cystatin B-Knockout Mouse Model of Progressive Myoclonus Epilepsy. *The American Journal of Pathology*. 2010; 177(5):2256–67. <https://doi.org/10.2353/ajpath.2010.100461> PMID: 20889561
33. Sullivan KD, Evans D, Pandey A, Hraha TH, Smith KP, Markham N, et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. *Scientific Reports*. 2017; 7(1):14818. <https://doi.org/10.1038/s41598-017-13858-3> PMID: 29093484
34. Kaur G, Gauthier SA, Perez-Gonzalez R, Pawlik M, Singh AB, Cosby B, et al. Cystatin C prevents neuronal loss and behavioral deficits via the endosomal pathway in a mouse model of down syndrome. *Neurobiology of Disease*. 2018; 120:165–73. <https://doi.org/10.1016/j.nbd.2018.08.025> PMID: 30176349
35. Im E, Jiang Y, Stavrides PH, Darji S, Erdjument-Bromage H, Neubert TA, et al. Lysosomal dysfunction in Down syndrome and Alzheimer mouse models is caused by v-ATPase inhibition by Tyr(682)-phosphorylated APP  $\beta$ CTF. *Sci Adv*. 2023; 9(30):eadg1925. Epub 20230726. <https://doi.org/10.1126/sciadv.adg1925> PMID: 37494443.
36. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. *Nat Genet*. 1998; 20(3):251–8. <https://doi.org/10.1038/3059> PMID: 9806543.
37. Shannon P, Pennacchio LA, Houseweart MK, Minassian BA, Myers RM. Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. *J Neuropathol Exp Neurol*. 2002; 61(12):1085–91. <https://doi.org/10.1093/jnen/61.12.1085> PMID: 12484571.